Skip to content
Storytelling Co – Lifestyle
Author:
Protagonist Therapeutics
Protagonist Therapeutics to Present Phase 3 VERIFY and Long-Term Rusfertide Data at the 2026 European Hematology Association Congress
June 1, 2026
Protagonist Therapeutics to Participate in Two Investment Bank Conferences in June 2026
May 28, 2026
Protagonist Reports First Quarter 2026 Financial Results and Provides Corporate Update
May 5, 2026
Protagonist Therapeutics Announces U.S. FDA Approval of ICOTYDE(TM) (icotrokinra) for the Treatment of Moderate to Severe Plaque Psoriasis
March 18, 2026
←
Previous Page
1
2